Compare MTEX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEX | CMMB |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 13.2M |
| IPO Year | 1998 | 2023 |
| Metric | MTEX | CMMB |
|---|---|---|
| Price | $6.95 | $1.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 2.3K | ★ 69.4K |
| Earning Date | 05-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 210.00 | 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $117,866,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.14 | $0.87 |
| 52 Week High | $12.45 | $3.86 |
| Indicator | MTEX | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 36.68 |
| Support Level | $6.94 | $0.88 |
| Resistance Level | $7.68 | $1.64 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 95.29 | 0.00 |
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.